Carcinoma

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
tisdag, maj 28, 2024
Research, Diabetes, Fitness & Nutrition, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Patient, Dana–Farber Cancer Institute, UC, Pembrolizumab, HNSCC, Head, SMA, Poster, Neoplasm, Rock, DRAGON, Melanoma, Publication, ASCO, Abstract, Society, Carcinoma, DFCI, Gongshi, Pharmaceutical industry

“In addition, biomarker data indicated that treatment with SRK-181 is associated with an enhanced proinflammatory microenvironment and increased anti-tumor activity.

Key Points: 
  • “In addition, biomarker data indicated that treatment with SRK-181 is associated with an enhanced proinflammatory microenvironment and increased anti-tumor activity.
  • - Biomarker data showed that the SRK-181 + pembrolizumab treatment combination created an enhanced proinflammatory microenvironment in anti-PD-(L)1 resistant patients.
  • These results will be presented at the ASCO Annual Meeting in an oral presentation, details of which can be found below.
  • The presentations will be made available in the Publications & Posters section of Scholar Rock’s website following the conference.

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

Retrieved on: 
fredag, maj 24, 2024
Merck & Co., Progression-free survival, Pembrolizumab, Kaplan–Meier estimator, CFS, Toxicity, Metastasis, Bladder cancer, Carcinoma, FDA, PFS, Safety, Fast track (FDA), MD, ITT, ASCO, Merck, CIS, NMIBC, Society, Carcinoma in situ, Dor, Annual general meeting, Pharmaceutical industry

The data will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting from May 31-June 4, in Chicago, IL.

Key Points: 
  • The data will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting from May 31-June 4, in Chicago, IL.
  • “There is a significant unmet need for new and innovative treatments for patients suffering with bladder cancer.
  • As of May 17, 2024, the CR rate in the ITT population at 24 months was 54% (19/35) (95% CI, 37-71%).
  • To learn more about the results from BOND-003 you may read the Company’s press release issued on May 3, 2024.

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Index, Patient, Carcinoma, MTD, Fudan University, Safety, Maxima and minima, Shanghai Cancer Center, CSPC, ASCO, Poster, Society, MUC

NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No.

Key Points: 
  • NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No.
  • 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released.
  • The poster will update data contained in the abstract [cut-off mid-January 2024] with approximately 3 months additional clinical data [cut-off end of April 2024] from dose escalation and PK cohorts.
  • Corbus has commenced a Phase 1 dose escalation study in the U.S. and dosed the first patient in April 2024.

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Conditional, Patient, PFS, SAN, NSCLC, CAB, Ipilimumab, PD-1, ASCO, Poster, Carcinoma, Society, Observation, BRAF, Therapy, DLT, Nivolumab, Annual general meeting, Pharmaceutical industry

SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced expanded data at an upcoming presentation entitled, “Phase 1 study of evalstotug (BA3071), an anti-CTLA-4 Conditionally Active Biologic, in combination with nivolumab in advanced solid tumors”, demonstrating confirmed responses with a potentially differentiated tolerability profile with the Company’s novel, conditionally active anti-CTLA-4 agent, evalstotug, in combination with anti-PD-1 therapy. The poster will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois on Saturday, June 1, 2024.

Key Points: 
  • The poster will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois on Saturday, June 1, 2024.
  • “Given the emerging clinical profile observed, we believe evalstotug has the potential to be best-in-class CTLA-4 antibody and holds the promise to be used as often as a PD-1 inhibitor,” said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. “Strikingly, we have observed prolonged PFS of greater than 10 months and confirmed responses at high doses (350 mg), of evalstotug, suggesting increased exposure of CTLA-4 blockade in combination with PD-1 inhibition drives clinical benefit.
  • We continue to enroll in the Phase 2 first-line melanoma and mutated NSCLC combination cohorts at the 700 mg flat dose and we anticipate moving to the 1 gram flat dose in June following clearance of the DLT observation period and remain on track for monotherapy and combination data readouts later this year.
  • We anticipate enabling a Phase 3 trial of evalstotug in first-line metastatic or unresectable BRAF-mutated melanoma in the second half of this year.

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

Retrieved on: 
torsdag, maj 23, 2024
SCLC, R&D, PET, Patient, Mesothelioma, Pharmacokinetics, Thrombocytopenia, Liver, News, Male, Therapy, Malignancy, Safety, Carcinoma, PD-1, Melanoma, Incidence, PR, Aes, PD-L1, Combination therapy, Pharmaceutical industry

Five clinical responses were observed, all in patients who previously received checkpoint inhibitors.

Key Points: 
  • Five clinical responses were observed, all in patients who previously received checkpoint inhibitors.
  • A durable partial response (PR) in a patient with small-cell lung cancer (SCLC) converted to a complete response, as confirmed by PET scan.
  • Four additional PRs were also observed, 3 of 11 (27.3%) patients with melanoma (2 confirmed, one unconfirmed) and one of four (25%) patients with mesothelioma (PR confirmed).
  • CTX-471 monotherapy was observed to be generally well-tolerated, with the majority of adverse events (AEs) being Grade 1-2.

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Uveal melanoma, Patient, Headache, DL2, Carcinoma, Plasma, Acute myeloid leukemia, PD, Thrombocytopenia, Toxicity, ACC, Nausea, Black Majesty, Messenger, Pharmacodynamics, Therapy, Grade 3, Safety, Acute lymphoblastic leukemia, Arm, CDKN1A, MD, Blood, AML, Efficacy, MPN, ALL, Biomarker, ASCO, Șaeș, MDM2, Fatigue, Poster, Society, TPD, Adenoid cystic carcinoma, Aes, Merkel-cell carcinoma, Resource, Vomiting, MCC, DLT, Annual general meeting, Pharmaceutical industry

WATERTOWN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced new clinical data for KT-253, a first-in-class MDM2 degrader, from its ongoing Phase 1 dose escalation trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 – June 4, 2024, in Chicago, Illinois. Results released in an ASCO abstract today include a data cut-off of January 26, 2024.

Key Points: 
  • Results released in an ASCO abstract today include a data cut-off of January 26, 2024.
  • “We continue to see encouraging data from the trial’s dose escalation phase demonstrating potent upregulation of p53 biomarkers and signs of antitumor activity in patients.
  • The Company expects to complete the study and share additional clinical data to inform the program’s next development steps in 2024 at an upcoming medical meeting.
  • Kymera is also developing a biomarker-based patient selection strategy for subsequent development beyond Phase 1a and is expected to present data at a medical meeting this year.

Amplexd Therapeutics, Innovating to Revolutionize the Future of Non-Invasive HPV-induced Cervical Intraepithelial Neoplasia (CIN) Treatments for the Prevention of Cervical Cancer: Developed by Women for Women

Retrieved on: 
tisdag, maj 21, 2024
Intraepithelial neoplasia, HPV, Cervical cancer, Diagnosis, Therapy, IND, Disease, Trauma, Cervical intraepithelial neoplasia, MD, Cervical, EGCG, Woman, Carcinoma, Physician, CIN, Entrepreneurship

The Company has secured US$2 Million for this initiative from an Asia-based life sciences focused family office.

Key Points: 
  • The Company has secured US$2 Million for this initiative from an Asia-based life sciences focused family office.
  • “The funding marks a major milestone in our R&D efforts for our two therapies after extremely promising preclinical studies were completed.
  • CIN results from certain oncogenic varieties of HPV, which can transform cervical cells into invasive cancer if left untreated.
  • My hope is that once approved, others can have an experience better than my own, without compromising quality of care,” Rahman added.

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
måndag, maj 20, 2024
Cream, Asset purchase agreement, Patient, PTCH1, Darier's disease, Prescription, United States district court, Patent, First, Nevoid basal-cell carcinoma syndrome, Clinical trial, FDA, Abbreviated New Drug Application, NESS, Skin, Bank statement, Psoriasis, Dermatology, Neoplasm, Genetic disorder, BCC, Cell, Compassion, Research, SMO, Autosome, District court, Carcinoma, Sol–gel process, Pharmaceutical industry

Highly encouraging clinical response for SGT-210 from a Compassionate use treatment for a pediatric patient suffering from an ultra-rare disease.

Key Points: 
  • Highly encouraging clinical response for SGT-210 from a Compassionate use treatment for a pediatric patient suffering from an ultra-rare disease.
  • According to IQVIA, the annual market sales in the 12 months ended in January 2024 for Zoryve® Cream were approximately $ 95 million.
  • We also initiated a proof-of-concept study for SGT-210 (topical erlotinib) in patients with Darier disease, with results expected in H1/2025.
  • As a result, previously reported revenue for the first quarter of 2023 was revised as reflected in the below income statement.

Amplexd Therapeutics, Innovating to Revolutionize the Future of Non-Invasive HPV-induced Cervical Intraepithelial Neoplasia (CIN) Treatments for the Prevention of Cervical Cancer: Developed by Women for Women

Retrieved on: 
måndag, maj 20, 2024
Intraepithelial neoplasia, HPV, Cervical cancer, Diagnosis, Therapy, IND, Disease, Trauma, Cervical intraepithelial neoplasia, MD, Cervical, EGCG, Woman, Carcinoma, Physician, CIN, Entrepreneurship

The Company has secured US$2 Million for this initiative from an Asia-based life sciences focused family office.

Key Points: 
  • The Company has secured US$2 Million for this initiative from an Asia-based life sciences focused family office.
  • “The funding marks a major milestone in our R&D efforts for our two therapies after extremely promising preclinical studies were completed.
  • CIN results from certain oncogenic varieties of HPV, which can transform cervical cells into invasive cancer if left untreated.
  • My hope is that once approved, others can have an experience better than my own, without compromising quality of care,” Rahman added.

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
måndag, maj 20, 2024
Insurance, Patient, Hepatectomy, Liver disease, PMDA, Marketing, McGill University Health Centre, Colorectal cancer, KPC, Clinical trial, Neoplasm, Government, D&O, Head, Safety, Alpha Sigma Tau, Congress, Pancreatic cancer, Brain, Carcinoma, Rambam Health Care Campus, Lung cancer, Alpha, G&A, Liver cancer

JERUSALEM, May 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported first quarter 2024 financial results and provided a corporate update.

Key Points: 
  • Alpha Tau anticipates remaining adequately capitalized to support all of these programs over the coming years," he concluded.
  • In May, preclinical data demonstrating an abscopal immune effect in pancreatic murine tumor models was presented at ESTRO 2024 Congress in Glasgow.
  • Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone.
  • Targeting completion of patient recruitment in the ReSTART U.S. multi-center pivotal trial in recurrent cutaneous squamous cell carcinoma in H2 2024.